[Retracted] Rivaroxaban attenuates thrombosis by targeting the NF-κB signaling pathway in a rat model of deep venous thrombus.

Following the publication of this article, an interested reader made us aware that the authors of the above paper had misappropriated certain of the data that had been published previously in three different papers. Specifically, Fig. 2A, B and G in the above paper appeared to be derived from Figs. 2A, 3 and 1A, respectively, of the paper by CM Ripplinger, CW Kessinger, C Li, JW Kim, JR McCarthy, R Weissleder, PK Henke, CP Lin and FA Jaffer (Arterioscler Thromb Vasc Biol 32: 2616‑2624, 2012). Figs. 2E, F, H, I and J in the above paper appeared to be derived from Figs. 1, 2A, 2D, 5E and 3F, respectively, of the paper by ML von Brühl, K Stark, A Steinhart, S Chandraratne, I Konrad, M Lorenz, A Khandoga, A Tirniceriu, R Coletti, M Köllnberger, et al (J Exp Med 209: 819‑835, 2012). Fig. 6C in the above paper appeared to be derived from Fig. 2D in the paper by CW Kessinger, JW Kim, PK Henke, B Thompson, JR McCarthy, T Hara, M Sillesen, RJ Margey, P Libby, R Weissleder, et al [PLoS One 10(2): e0116621, 2015], and Fig. 6H in the above paper appeared to be derived from Fig. 4 in the paper by von Brühl et al. Following an internal enquiry, the Editor of International Journal of Molecular Medicine has determined that the claim should be upheld; therefore, the Editorial Board has decided that the article should be retracted. All efforts were made to contact the corresponding author of the above article. The Editor apologizes to the readership of the Journal for any inconvenience caused. [the original article was published in the International Journal of Molecular Medicine 40: 1869‑1880, 2017; DOI: 10.3892/ijmm.2017.3166].